JPMorgan (JPM) has broken out to new highs this week, but sits near a perilous technical level, writ...
Bristol-Myers Bets on Diabetes and Oncology
01/24/2014 8:00 am EST
As a group, large pharma has lagged the market; slow growth and expiring patents present a problem not easily solved, explains Genia Turanova, editor of Leeb Income Performance.
Bristol-Myers Squibb (BMY) has performed better than the rest of the group. The company has been able to replace some of its best-selling medicines, with the resulting growth being stronger than that of the two other drug companies we're holding.
One area where Bristol-Myers has excelled is Immuno-Oncology, where it recently presented promising clinical data. Immuno-Oncology is an innovative, and, potentially, revolutionary approach to cancer research that seeks to harness the body's own immune system to fight tumor cells.
Bristol-Myers is at the forefront of this science with several compounds either in development or under investigation for use in a variety of cancers, as well as an approved Immuno-Oncology medicine that is being studied for new uses.
Another strong area for Bristol-Myers is diabetes, and it continues to strengthen its position here.
The relatively recent purchase of Amylin (which the company bought in partnership with AstraZeneca) gave Bristol-Myers a leg-up in the Glucagon-like peptide-1 (GLP-1) space. Amilyn has already been integrated into Bristol-Myers operations.
Moreover, Bristol-Myers is widely expected to get a positive FDA recommendation shortly, for its diabetes treatment Forxiga (already launched in Europe), also a collaboration with AstraZeneca.
Analysts predict that sales of the drug could exceed $1 billion by 2020. The latest quarter showed strong growth in another Type-2 diabetes medicine, Onglyza, with sales up 19% year over year; all said, sales from the diabetes-related drugs totaled $411 million in the latest quarter.
Bristol-Myers trades at a much higher valuation (on a P/E basis) than its pharma peers. This is justified, in our opinion, given its better growth prospects.
More from MoneyShow.com:
Related Articles on STOCKS
Crude oil prices should be moving higher than they are, writes Phil Flynn, senior energy analyst at ...
Cognizant Technology Solutions (CTSH) began operations in 1994 as an in-house technology development...
Neil Macneale fcouses on stocks that have announced upcoming splits; here, the editor of 2-for-1 Sto...